roniciclib
Small moleculeexperimental
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01188252)
Timeline
Indications
Mechanism of action
- Cyclin-dependent kinaseINHIBITOR
Cyclin-dependent kinase inhibitor
- Cyclin-dependent kinase 1 (CDK1) ↗
- Cyclin-dependent kinase 4 (CDK4) ↗
- Cyclin-dependent kinase 2 (CDK2) ↗
- Cyclin-dependent-like kinase 5 (CDK5) ↗
- Cyclin-dependent kinase 6 (CDK6) ↗
- Cyclin-dependent kinase 7 (CDK7) ↗
- Cyclin-dependent kinase 3 (CDK3) ↗
- Cyclin-dependent kinase 16 (CDK16) ↗
- Cyclin-dependent kinase 18 (CDK18) ↗
- Cyclin-dependent kinase 8 (CDK8) ↗
- Cyclin-dependent kinase 17 (CDK17) ↗
- Cyclin-dependent kinase 11B (CDK11B) ↗
- Cyclin-dependent kinase 15 (CDK15) ↗
- Cyclin-dependent kinase 19 (CDK19) ↗
- Cyclin-dependent kinase 14 (CDK14) ↗
- Cyclin-dependent kinase 9 (CDK9) ↗
- Cyclin-dependent kinase 10 (CDK10) ↗
- Cyclin-dependent kinase 13 (CDK13) ↗
- Cyclin-dependent kinase 20 (CDK20) ↗
- Cyclin-dependent kinase 12 (CDK12) ↗
- Cyclin-dependent kinase 6
- Cyclin-dependent kinase 9
- Cyclin-dependent kinase 2
- Cyclin-dependent kinase 1
- Cyclin-dependent kinase 3
- Cyclin-dependent kinase 7
- Cyclin-dependent kinase 4
- Cyclin-dependent kinase 5
- Serine/threonine-protein kinase PCTAIRE-1
- Serine/threonine-protein kinase PCTAIRE-3
- Cell division protein kinase 8
- PITSLRE serine/threonine-protein kinase CDC2L1
- Serine/threonine-protein kinase PFTAIRE-2
- Cell division cycle 2-like protein kinase 6
- Serine/threonine-protein kinase PFTAIRE-1
- Serine/threonine-protein kinase PCTAIRE-2
- Cyclin-dependent kinase 10
- Cyclin-dependent kinase 13
- Cyclin-dependent kinase 2 and 4 (CDK2 and CDK4)
- CDK2/CDK4
- Cyclin-dependent kinase 20
- Cyclin-dependent kinase 12
- Cyclin-dependent kinase 4/6
- Cyclin-dependent kinase 8/19
- CDK4/CDK9
- Cyclin-dependent kinase 12/13
- CDK4/CDK1
- Cyclin-dependent kinase 2/4/6
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=N)(=O)C3CC3)cc2)ncc1C(F)(F)F- Mol. weight
- 430.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4442620 ↗
- ChEMBLCHEMBL3544942 ↗
Also known as
- bay1000394
- bay 1000394
- bay 1000394
- bay 1000394
- bay-1000394
- bay-1000394
- roniciclib
- roniciclib
- roniciclib
- roniciclib
- s-cyclopropyl-s-(4-((4-((2-hydroxy-1-methylpropyl)oxy)-5-(trifluoromethyl)pyrimidin-2-yl)amino)phenyl)sulfoximide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02656849 | Phase 2 | Feb 1, 2016 | Bayer, Harvard University |
| NCT02522910 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2015 | Yonsei University |
| NCT02457351 | Phase 1 | Jul 1, 2015 | Bayer |
| NCT02390154 | Phase 1 | Apr 1, 2015 | Bayer |
| NCT02161419 | Phase 2 | Jul 30, 2014 | Bayer |
| NCT02047890 | Phase 1 | May 19, 2014 | Bayer |
| NCT01573338 | Phase 1/Phase 2 (Phase 2) | Feb 25, 2013 | Bayer |
| NCT01335256 | Phase 1 | Dec 1, 2010 | Bayer |
| NCT01188252 | Phase 1 | Aug 1, 2010 | Bayer |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 8 | 7 | 2 | 2010 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1